Please login to the form below
Kaletra
This page shows the latest Kaletra news and features for those working in and with pharma, biotech and healthcare.
WHO to test three more potential COVID-19 treatments
Hydroxychloroquine and lopinavir/ritonavir (AbbVie’s Kaletra) are not being used currently, while UK-based biotech Synairgen has an ongoing trial investigating an inhaled formulation of Interferon-beta-1a in
Latest news
-
AbbVie’s HIV therapy Kaletra fails to show efficacy in COVID-19
In the RECOVERY trial, 1, 616 patients were randomised to receive Kaletra, compared to 3, 424 patients who received standard-of-care. ... In June, the World Health Organization halted the evaluation of Kaletra treatment in its SOLIDARITY trial of
-
AbbVie, Amgen and Takeda team up for joint COVID-19 trial
Unfortunately, not all efforts to repurpose drugs have proved successful, with AbbVie’s Kaletra HIV treatment (lopinavir/ritonavir) failing to show efficacy against the virus.
-
UPDATED: Gilead drops remdesivir’s orphan drug designation
Gilead’s decision to gain orphan drug designation for remdesivir strongly contrasts AbbVie’s choice to suspend patent rights to its HIV treatment Kaletra (aluvia), which is also currently being studied
-
AbbVie suspends Kaletra patent rights as COVID-19 drug trials advance
That includes AbbVie, whose HIV treatment Kaletra (aluvia) has already been identified as a potential treatment for the novel coronavirus disease. ... its global patents for Kaletra to allow for generic copies to be made.
-
Trump calls on FDA to cut ‘red tape’ as coronavirus drug trials gather pace
There was disappointing news after a clinical trial of AbbVie’s HIV therapy Kaletra (lopinavir/ritonavir) – conducted by doctors in China in 199 severely-ill COVID-19 patients – found no benefit
More from news
Approximately 3 fully matching, plus 28 partially matching documents found.
Latest Intelligence
-
As COVID-19 takes over the world, biopharma fights back
19. Kaletra combines two antivirals, lopinavir and ritonavir, and is already approved for use as a treatment for HIV. ... who].were late in infection and already had considerable tissue damage”. However, the study also found that Kaletra is unable to
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- How an AI algorithm might save your life
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
Mednet Group
PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
